首页> 美国卫生研究院文献>Biomarker Insights >Biomarkers for Sepsis: What Is and What Might Be?
【2h】

Biomarkers for Sepsis: What Is and What Might Be?

机译:败血症的生物标志物:什么是什么可能是什么?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Every year numerous individuals develop the morbid condition of sepsis. Therefore, novel biomarkers that might better inform clinicians treating such patients are sorely needed. Difficulty in identifying such markers is in part due to the complex heterogeneity of sepsis, resulting from the broad and vague definition of this state/condition based on numerous possible clinical signs and symptoms as well as an incomplete understanding of the underlying pathobiology of this complex condition. This review considers some of the attempts that have been made so far, looking at both the pro- and anti-inflammatory response to sepsis, as well as genomic analysis, as sources of potential biomarkers. Irrespective, for functional biomarker(s) of sepsis to successfully translate from the laboratory to a clinical setting, the biomarker must be target specific and sensitive as well as easy to implement/interpret, and be cost effective, such that they can be utilized routinely in patient diagnosis and treatment.
机译:每年都有许多人患上败血症。因此,迫切需要能够更好地指导临床医生治疗此类患者的新型生物标志物。难以鉴定此类标志物的部分原因是败血症具有复杂的异质性,这是由于根据多种可能的临床体征和症状对该状态/病状进行了广泛而模糊的定义,并且对这种复杂病状的潜在病理生物学认识不全面。这篇综述考虑了迄今为止所做的一些尝试,将败血症的促炎症反应和消炎反应以及基因组分析作为潜在生物标记物的来源。无论如何,脓毒症的功能性生物标志物要成功地从实验室转化为临床环境,生物标志物必须具有针对性和敏感性,并且易于实施/解释,并且具有成本效益,因此可以常规使用在患者的诊断和治疗中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号